Program Leader
Kenneth D. Tew, Ph.D. D.Sc. Scientific Goal
To provide a platform for drug discovery and development projects and amalgamate with mechanism of action and drug resistance approaches; laboratory findings will guide the development of phase I clinical trials. Interactions
The Developmental Cancer Therapeutics program brings together investigators from six different disciplines at MUSC and the University of South Carolina who focus scientific efforts in areas that are relevant to treatment of cancer. By combining high throughput technology provided by the Hollings Cancer Center Drug Discovery Core with drug development strategies at both the preclinical and clinical level, the program members seek to establish novel approaches to the therapeutic management of human cancer. By implication, research seeks to identify novel agents that have interesting pharmacology that is distinct from existing drug entities. In addition, mechanism of action studies and detailed analyses of drug resistance patterns supplement the practical development of new drug entities. Translational efforts involve clinical investigations that implement Phase I/II studies; a Drug Metabolism and Clinical Pharmacology Core supports these efforts. Contact Us
To find out more about this research program, e-mail the Program Leader: Kenneth D. Tew, Ph.D., D.Sc.
tewk@musc.edu » Hematologic Malignancies
| 
